Panadol Osteo is formulated with a
patented bilayer technology for effective
pain relief lasting up to 8 hours*4
Extended duration of action provides improved symptom control,6 which may improve treatment adherence and reduce switching.
The sustained-release formulation of Panadol Osteo allows extended duration of benefit
Pain relief lasting up to 24 hours can be achieved with two Panadol Osteo 665 mg tablets taken three times a day4 (vs immediate-release paracetamol taken four times daily)6
At steady state, Panadol Osteo rapidly delivers therapeutic plasma levels of paracetamol, and maintains those levels for up to 8 hours5
Sustained-release Panadol Osteo delivers optimum paracetamol relief in three daily doses
Adapted from Bacon TH, et al. 22nd Annual Scientific Meeting of the Australian Pain Society. Abstract. 2001.
Open-label, single centre, multiple dose, two-way crossover, phase I pharmacokinetic study in healthy subjects (N = 26).5
Prolonged time above therapeutic threshold may lead to clinical benefits in OA including:6
Greater overall symptom relief
Persistence of symptom relief through sleeping hours
Potential for less morning pain due to extended effect
Less frequent dosing may improve treatment adherence
Improved symptom control vs immediate-release paracetamol
Twice as many patients with mild-to-moderate knee OA pain preferred Panadol Osteo over immediate-release paracetamol (68% vs 32%, respectively; p=0.02)6
Panadol Osteo significantly reduced pain from walking on a flat surface by 34% vs baseline (p<0.001)6
Overall knee pain and pain upon waking were significantly improved with Panadol Osteo vs immediate-release paracetamol (p<0.02)6
Adapted from Benson M, et al. J Int Med Res. 2009;37:1321-35. Multicentre, randomised, open-label, two-way crossover trial in 210 patients with knee OA.6
VAS = Visual Analog Scale
Panadol Osteo has a suitability profile you can trust*
Paracetamol, the active ingredient in Panadol
Osteo, has a low incidence of adverse events*
and few drug-drug interactions and is generally
suitable in polypharmacy†4
When used as directed on the label, paracetamol has excellent GI tolerance and a very low risk of renal or hepatic side effects7,8
Paracetamol should be used with caution in patients with renal or hepatic impairment.4
As with all medications, patients using
long-term, regular paracetamol should be medically monitored.8,9
At recommended doses of 4 g/day, the patented bilayer technology in Panadol Osteo, with its sustained-release component, ensures that each single dose of 2 tablets does not exceed the plasma concentrations of immediate-release paracetamol10
